Ran Meng Selected Research

Batroxobin

1/2021	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review.
1/2019	Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience.
10/2018	The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ran Meng Research Topics

Disease

23	Stroke (Strokes) 02/2022 - 05/2006
17	Neoplasms (Cancer) 08/2021 - 01/2011
11	Thrombosis (Thrombus) 06/2022 - 12/2018
9	Inflammation (Inflammations) 01/2022 - 01/2010
9	Insulin Resistance 01/2021 - 01/2010
9	Ischemic Stroke 01/2019 - 06/2011
7	Pathologic Constriction (Stenosis) 06/2022 - 01/2019
7	Infarction (Infarctions) 08/2019 - 06/2011
7	Acute Promyelocytic Leukemia 09/2014 - 11/2003
6	Hemorrhage 06/2022 - 09/2018
6	Ischemia 12/2021 - 05/2009
6	Cerebral Hemorrhage 10/2021 - 05/2009
5	Venous Thrombosis (Deep-Vein Thrombosis) 06/2022 - 01/2018
5	Obesity 01/2021 - 08/2015
5	Breast Neoplasms (Breast Cancer) 01/2019 - 04/2013
5	Leukemia 01/2019 - 11/2003
4	Thrombophilia 11/2022 - 02/2021
4	Body Weight (Weight, Body) 01/2021 - 01/2013
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2011
4	Cerebral Infarction 01/2020 - 01/2006
3	Alzheimer Disease (Alzheimer's Disease) 05/2022 - 01/2022
3	Infections 01/2022 - 02/2012
3	Vascular Diseases (Vascular Disease) 12/2021 - 08/2018
3	Brain Ischemia (Cerebral Ischemia) 10/2021 - 07/2015
3	Sepsis (Septicemia) 01/2021 - 12/2018
3	Headache (Headaches) 01/2021 - 03/2019
3	Hypothermia 01/2019 - 09/2017
3	Intracranial Sinus Thrombosis (Sinus Thrombosis) 10/2018 - 05/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2013 - 01/2011
3	Carcinoma (Carcinomatosis) 08/2013 - 01/2011
2	Hyperhomocysteinemia 02/2022 - 11/2021
2	Hypertension (High Blood Pressure) 02/2022 - 08/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2017
2	Hypoxia (Hypoxemia) 12/2021 - 08/2013
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2021 - 01/2019
2	Edema (Dropsy) 01/2021 - 01/2020
2	Cognitive Dysfunction 01/2021 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2011
2	Heart Failure 12/2020 - 07/2015
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2020 - 10/2018
2	Liver Diseases (Liver Disease) 03/2019 - 01/2016
2	Reperfusion Injury 08/2018 - 02/2013
2	Necrosis 08/2017 - 12/2004
2	Transient Ischemic Attack 04/2017 - 07/2015
2	Hyperglycemia 12/2016 - 01/2011
2	Glucose Intolerance 01/2016 - 01/2013
2	Carcinogenesis 01/2016 - 08/2013
2	Glioma (Gliomas) 11/2015 - 07/2015

Drug/Important Bio-Agent (IBA)

13	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2006
11	Arsenic Trioxide (Trisenox)FDA Link 09/2014 - 11/2003
8	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2010
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2011
6	salicylhydroxamic acid (SHAM)IBA 01/2019 - 07/2015
5	Insulin (Novolin)FDA Link 01/2022 - 01/2010
5	Oxygen (Dioxygen)IBA 10/2021 - 02/2013
5	Erythropoietin FDA Link 08/2019 - 01/2013
5	IntegrinsIBA 08/2013 - 01/2011
5	tetraiodothyroacetic acid (TA(4))IBA 06/2013 - 01/2011
5	Aligeron (AS 2)IBA 01/2010 - 11/2003
4	Pharmaceutical PreparationsIBA 04/2021 - 05/2015
4	Fibrinogen (Factor I)FDA Link 01/2021 - 06/2011
4	SilymarinIBA 01/2021 - 01/2016
4	fibrin fragment D (D-dimer)IBA 01/2021 - 05/2009
4	Estrogen ReceptorsIBA 07/2017 - 01/2011
4	Messenger RNA (mRNA)IBA 08/2016 - 02/2015
4	Thyroid HormonesIBA 08/2013 - 01/2011
3	Blood Glucose (Blood Sugar)IBA 02/2022 - 01/2013
3	Phosphotransferases (Kinase)IBA 10/2021 - 08/2017
3	BatroxobinIBA 01/2021 - 10/2018
3	LipopolysaccharidesIBA 01/2021 - 12/2018
3	LipidsIBA 03/2019 - 01/2017
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2018 - 01/2006
2	Warfarin (Coumadin)FDA LinkGeneric 04/2022 - 05/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2022 - 12/2021
2	Peptides (Polypeptides)IBA 01/2022 - 01/2022
2	AlbuminsIBA 01/2022 - 07/2021
2	CytokinesIBA 12/2021 - 01/2019
2	Oral ContraceptivesIBA 11/2021 - 02/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 01/2021
2	CalciumIBA 10/2021 - 10/2004
2	Indicators and Reagents (Reagents)IBA 07/2021 - 01/2019
2	HMGB1 Protein (HMG1)IBA 01/2021 - 01/2019
2	Mannitol (Osmitrol)FDA LinkGeneric 06/2020 - 09/2014
2	Neuroprotective AgentsIBA 08/2019 - 05/2013
2	CateninsIBA 01/2019 - 11/2015
2	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2018
2	dihydrocapsaicinIBA 01/2019 - 09/2017
2	ORALIT (ORS)IBA 01/2019 - 01/2019
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2017 - 02/2015
2	sodium-hydrogen exchanger regulatory factorIBA 08/2016 - 10/2013
2	Guanylate KinasesIBA 11/2015 - 07/2015
2	EnzymesIBA 02/2015 - 02/2013

Therapy/Procedure

19	Therapeutics 06/2022 - 11/2003
5	Intravenous Infusions 10/2018 - 11/2003
4	Stents 06/2022 - 12/2018
2	Ligation 01/2021 - 12/2018
2	Punctures 01/2021 - 12/2018
2	Induced Hypothermia 01/2019 - 09/2017
2	Thrombectomy 07/2018 - 05/2013